Members of the HIVACAR consortium and Asphalion attended an ITF meeting at the EMA in London in May to obtain feedback on the HIVACAR project whose main objective is to conduct a Phase I/II a clinical trial to test an innovative therapeutic approach to control HIV infection. The therapeutic approach combines immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents.
The ITF is a multidisciplinary group from the EMA that includes scientific, regulatory and legal competences and is specifically focussed on supporting early stage development projects.
The ITF meeting was very positive and represented successful completion of one of the first milestones for the Horizon 2020 project. The ITF and HIVACAR discussed the rational and design of the therapeutic strategy and the clinical trial and important aspects related to non-clinical safety as well as to the production and characterisation of the vaccines.
HIVACAR is an EC funded consortium and project funded under the EC Framework Programme for Research, Innovation and Technology Horizon 2020 call H2020 SC1-PM-09-2016, New therapies for chronic diseases of which Asphalion is a partner.
If you are interested and wish to have further information about HIVACAR project or Horizon 2020 program please contact us at H2020@asphalion.com
Hivacar: This Project has received funding from the European Union?s Horizon 2020 research and innovation programme under grant agreement No 731626
